TEMPO-3), adding tavapadon increased “on” time without troublesome dyskinesia and reduced “off” time.
Long-term follow-up data suggested sustained benefits for many participants over months, with a safety profile that researchers described as generally favorable.
Common side effects reported across studies included nausea, headache, and dizziness. These were mostly mild to moderate, and serious events occurred at rates similar to or slightly higher than placebo in some trials. Importantly, hallucinations and impulse control issues remained comparable to placebo levels, which aligns with the drug’s more targeted receptor profile.
Here is a